Published On: Wed, Oct 19th, 2016

Analyst Coverage: Lantheus Holdings, Inc. (LNTH)


Recently stock market analysts have updated their consensus ratings on shares of Lantheus Holdings, Inc. (LNTH).

Most recent broker ratings

09/23/2016 – Credit Suisse began new coverage on Lantheus Holdings, Inc. giving the company a “neutral” rating. They now have a USD 8 price target on the stock.

08/29/2016 – Lantheus Holdings, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 12 price target on the stock.

02/24/2016 – Lantheus Holdings, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 6 price target on the stock.

02/23/2016 – Lantheus Holdings, Inc. had its “neutral” rating reiterated by analysts at Robert W. Baird. They now have a USD 4 price target on the stock.

09/30/2015 – Lantheus Holdings, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

Lantheus Holdings, Inc. has a 50 day moving average of 8.46 and a 200 day moving average of 4.80. The stock’s market capitalization is 262.85M, it has a 52-week low of 1.76 and a 52-week high of 10.10.

The share price of the company (LNTH) was up +2.37%, with a high of 8.80during the day and the volume of Lantheus Holdings, Inc. shares traded was 396390.

Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.